USE OF PHARMACOECONOMICS/HEALTH ECONOMIC TOOLS (PE/HE) IN HEALTH CARE DECISION MAKING IN A MICRO LEVEL IN MEXICO.
Author(s)
Herman Soto-Molina, MES, Mr1, Silvia Guzman, MD, Research2, Omar Zanela, BA, Economics, Assistant3, Laura Cortés, MD, Medical Researcher, Internist4, Gustavo Martínez, MD, Medical Researcher51Universidad Autonoma del Estado de México, Toluca, Mexico; 2 Universidad Autónoma del Estado de México, Toluca, México, Mexico; 3 Centro de Investigación y Docencia Economicas CIDE A.C, México, Distrito Federal, Mexico; 4 Hospital de Especialidades, CMNO, IMSS, Guadalajara, Jalisco, Mexico; 5 Private Medicine, México, Distrito Federal, Mexico
OBJECTIVES: To evaluate micro-level health care decision makers' (DMs) basic knowledge level of PE/HE tools, their applications, advantages and obstacles. METHODS: a transversal survey (self-report questionnaire) was applied to DMs (Medical Doctors and Specialists) in a non-related forum, concerning PE/HE concept knowledge and utilization in the health care decision making process. Descriptive and multivariate analyses were performed. Results are expressed either as DMs' approval percentage, mean values or standard deviations (SD). RESULTS: 156 DMs answered the questionnaire, 82.89% males, mean age 45.4 (±10.9) and 17.33 previous experience years (±10.08). 30.13% were urologists, 16.67% general physicians, and 12.18% family physicians. The most relevant drug-prescribing characteristics were efficacy (88.46%) and safety and tolerability (55.13%), while publicity and patients' request were not considered relevant (42.34% and 28.78%, respectively); only 36.3% and 16.78% considered quality of life (QoL) and price of medication as relevant. 22.44% had taken a Management course, only 10.26% had prior PE/HE training, and 67.31% showed interest in getting trained in the field. Cost-benefit was the most-known concept (33.33%), but only correctly defined by 15.38%; cost-consequence was the least known (12.18%) and cost-utility was only well defined by 2.56%. Only 17.95% periodically review specialized literature, particularly the IMSS Medical Journal (35.71%). 76.92% showed interest in publications concerning medication's cost, 63.46% in hospitalization costs and 40.38% in disability and productivity loss costs. 24.36% affirm economic evaluation improves patients' QoL, and 14.74% see PE/HE as a resource and budget optimization tool. 21.15% had trouble using PE/HE information because of unfamiliarity (46.67%) and information problems (30.00%). 37.82% affirms economic evaluation studies' expected utility is very high. CONCLUSION: Mexican health care DMs lack PE/HE knowledge, so training in the area must be enhanced at all levels.
Conference/Value in Health Info
2007-09, ISPOR Latin America 2007, Cartagena, Colombia
Value in Health, Vol. 10, No. 6 (November/December 2007)
Code
PMC9
Topic
Health Policy & Regulatory
Disease
Multiple Diseases
Explore Related HEOR by Topic